BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CureLab, Inc., Canton Vaccine Firm, Plans North Dakota Move


12/17/2012 9:08:06 AM

Fargo biotechnology company Aldevron has been chosen to produce cancer vaccines being developed by a Boston-area research company that plans to move most of its operations to North Dakota. The DNA-based vaccines have shown promise in animal studies in suppressing lung and breast cancers, the Forum newspaper reported. CureLab Oncology will keep a lab and office in Canton, but plans to move most of its operations sometime next year to North Dakota, possibly to Fargo or Grand Forks, where it also is collaborating with Avianax, a biotech company at the University of North Dakota. The company will bring a few people to North Dakota but plans to hire local college and university graduates, CEO Alex Schneider said. ‘‘We already have put our foot on the soil,’’ Schneider said of the production partnership with Aldevron, which does custom DNA work for research labs around the world. The addition of CureLab to the area will help Fargo-Moorhead in its efforts to establish the area as a hub for the growing vaccine and biotech industries, said Michael Chambers, Aldevron’s chief executive.

Read at Boston Globe

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->